Feedback – BTOG Study Day 2023
Please complete this form to receive your CPD certificate, which will be sent as a PDF by email once your feedback has been validated. This may take a few days, thank you for your patience.
Please complete this form to receive your CPD certificate, which will be sent as a PDF by email once your feedback has been validated. This may take a few days, thank you for your patience.
Please complete this form to receive your CPD certificate, which will be sent as a PDF by email once your feedback has been validated. This may take a few days, thank you for your patience.
Originally live on Wednesday 8th November 2023, 18:00-19:10 Chaired by Professor Sanjay Popat, this webinar covered clinically impactful thoracic oncology highlights of ESMO 2023 held in Madrid. To view this event on demand, please register at www.btogwebinars.org If you have previously … Read More
Drug treatment of operable NSCLC Originally live 12th October, 2023, 6pm BST In the fourth roundtable in a series of Lung Cancer Sessions organized by VJOncology and the British Thoracic Oncology Group (BTOG), leading UK thoracic experts Sanjay Popat, Meenali … Read More
Originally live on Monday 25th September 2023, 18:00-19:30 Chaired by Professor Sanjay Popat, this webinar covered clinically impactful thoracic oncology highlights of WCLC 2023 held 9th to 12th September 2023 in Singapore. To view this event on demand, please register … Read More
Please complete this form to receive your CPD certificate, which will be sent as a PDF by email once your feedback has been validated. This may take a few days, thank you for your patience.
Please complete this form to receive your CPD certificate, which will be sent as a PDF by email once your feedback has been validated. This may take a few days, thank you for your patience.
NICE has published an update to the NICE Systemic anti-cancer therapy for advanced non‑small‑cell lung cancer: treatment options summary (PDF).
BTOG is disappointed that lorlatinib has not been recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in adults who have not had an ALK inhibitor (1st line, CROWN indication). This recommendation … Read More
Welcome to the inaugural BTOG trainee newsletter, where we aim to provide you with updates relevant to trainees working in the thoracic oncology space. In terms of content, the trainee newsletter will seek to summarise the ‘hot-off-the-press’ landmark papers, list … Read More